PALO
ALTO, Calif., Sept. 1,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals,
Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company
focused on the development of innovative therapies for hepatitis
delta virus (HDV) and other serious diseases, today announced that
members of its management team will participate in the following
upcoming investor conferences:
Citi's 17th Annual BioPharma Conference
- Date: Thursday, September 8,
2022
- Location: Boston, MA
- Format: One-on-one meetings
H.C. Wainwright 24th Annual Global Investment
Conference
- Date & Time: Monday, September 12,
2022 at 2:00 p.m. ET
- Location: New York, NY
- Format: Company presentation and one-on-one meetings
Baird Global Healthcare Conference
- Date & Time: Wednesday, September
14, 2022 at 3:45 p.m. ET
- Location: New York, NY
- Format: Company presentation and one-on-one meetings
A live webcast of each presentation will be available on the
Investors section of the Eiger BioPharmaceuticals website at
www.eigerbio.com. A replay of each presentation will be available
on the website for at least 90 days.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious diseases. The Eiger HDV platform includes
two first-in-class therapies in Phase 3 that target critical host
processes involved in viral replication. All five Eiger rare
disease programs have been granted FDA Breakthrough Therapy
designation: lonafarnib and peginterferon lambda for HDV, Zokinvy
for progeria, and avexitide for both congenital hyperinsulinism and
post-bariatric hypoglycemia.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-three-upcoming-investor-conferences-301616160.html
SOURCE Eiger BioPharmaceuticals, Inc.